Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer

A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette–Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®...

Descripción completa

Detalles Bibliográficos
Autores principales: Liem, Esmee I. M. L., Baard, Joyce, Cauberg, Evelyne C. C., Bus, Mieke T. J., de Bruin, D. Martijn, Laguna Pes, M. Pilar, de la Rosette, Jean J. M. C. H., de Reijke, Theo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581817/
https://www.ncbi.nlm.nih.gov/pubmed/28866819
http://dx.doi.org/10.1007/s12032-017-1033-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581817/
https://www.ncbi.nlm.nih.gov/pubmed/28866819
http://dx.doi.org/10.1007/s12032-017-1033-z

Ejemplares similares